Guide Acquisition - Summary of Transaction Price Determined and Allocated (Details) - Guide Therapeutics, Inc. - Merger Agreement $ in Thousands |
Feb. 23, 2021
USD ($)
|
---|---|
Transaction price | |
Fair value of equity instruments issued | $ 120,032 |
Technology and product contingent consideration liabilities | 36,513 |
Transaction costs | 2,531 |
Total transaction price | 159,076 |
Transaction price allocated | |
Cash acquired | 3,151 |
Prepaid expenses and other assets | 264 |
Property and equipment | 1,835 |
Other liabilities assumed | (1,427) |
Total transaction price | 159,076 |
In-Process Research and Development | |
Transaction price allocated | |
Intangible assets | 154,953 |
Assembled Workforce | |
Transaction price allocated | |
Intangible assets | $ 300 |
X | ||||||||||
- Definition Amount of transactions costs incurred by the acquirer. No definition available.
|
X | ||||||||||
- Definition Amount of contingent consideration liability for technology and product milestones incurred by the acquirer. No definition available.
|
X | ||||||||||
- Definition Business combination transaction price. No definition available.
|
X | ||||||||||
- Definition Business combination transaction price allocated. No definition available.
|
X | ||||||||||
- Definition Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
X | ||||||||||
- Definition Amount of equity interests of the acquirer, including instruments or interests issued or issuable in consideration for the business combination. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
X | ||||||||||
- Definition Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
X | ||||||||||
- Definition Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
X | ||||||||||
- Definition The amount of identifiable intangible assets recognized as of the acquisition date. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
X | ||||||||||
- Definition Amount of other liabilities due after one year or the normal operating cycle, if longer, assumed at the acquisition date. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
X | ||||||||||
- Definition The amount of property, plant, and equipment recognized as of the acquisition date. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
X | ||||||||||
- Definition Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
X | ||||||||||
- Details
|
X | ||||||||||
- Details
|
X | ||||||||||
- Details
|
X | ||||||||||
- Details
|